Trial Summary
What is the purpose of this trial?This trial tests a new therapy in adults with dermatomyositis. The therapy modifies their white blood cells to target and destroy harmful B cells, aiming to reset their immune system and reduce disease symptoms. This new treatment shows promising results in similar conditions.
Eligibility Criteria
This trial is for adults with dermatomyositis, an autoimmune disease. Participants must have their own T cells modified to target B cells that may be causing the disease. It's not specified who can't join, but typically those with other serious health issues or immune deficiencies might be excluded.Treatment Details
The study tests KYV-101 Anti-CD19 CAR T Therapy in adults with dermatomyositis. Patients' T cells are engineered to destroy B cells by recognizing CD19 protein, potentially resetting the immune system and alleviating the disease.
1Treatment groups
Experimental Treatment
Group I: Active Intervention with CAR TExperimental Treatment1 Intervention
All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen
KYV-101 is already approved in United States for the following indications:
🇺🇸 Approved in United States as KYV-101 for:
- Refractory Lupus Nephritis
- Stiff-Person Syndrome
- Myasthenia Gravis
- Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
- Primary and Secondary Progressive Multiple Sclerosis
Find a clinic near you
Research locations nearbySelect from list below to view details:
Stanford UniversityStanford, CA
Loading ...
Who is running the clinical trial?
Stanford UniversityLead Sponsor